Olivier Demaria
Marseille, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma.
Journal: Science immunology
Published: November 15, 2024
New immune cell engagers for cancer immunotherapy.
Journal: Nature reviews. Immunology
Published: December 06, 2023
Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]).
Journal: Critical care medicine
Published: October 11, 2022
Natural killer cell engagers in cancer immunotherapy: Next generation of immuno-oncology treatments.
Natural killer cell engagers in cancer immunotherapy: Next generation of immuno-oncology treatments.
Journal: European journal of immunology
Published: March 16, 2021
Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19.
Journal: Cellular & molecular immunology
Published: June 15, 2020
Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis.
Journal: Nature
Published: April 29, 2020
Publisher Correction: Harnessing innate immunity in cancer therapy.
Journal: Nature
Published: November 21, 2019
The commensal skin microbiota triggers type I IFN-dependent innate repair responses in injured skin.
The commensal skin microbiota triggers type I IFN-dependent innate repair responses in injured skin.
Journal: Nature immunology
Published: September 03, 2019
Last Updated: 09/26/2026